CN108576367A - 含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 - Google Patents
含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 Download PDFInfo
- Publication number
- CN108576367A CN108576367A CN201810215529.3A CN201810215529A CN108576367A CN 108576367 A CN108576367 A CN 108576367A CN 201810215529 A CN201810215529 A CN 201810215529A CN 108576367 A CN108576367 A CN 108576367A
- Authority
- CN
- China
- Prior art keywords
- parts
- dry powder
- polypeptide dry
- anserine
- trioxypurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 82
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 76
- 108010085443 Anserine Proteins 0.000 title claims abstract description 46
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 241000210053 Potentilla elegans Species 0.000 title claims abstract description 46
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 title claims abstract description 46
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000013361 beverage Nutrition 0.000 title claims abstract description 14
- 241000251468 Actinopterygii Species 0.000 claims abstract description 36
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims description 16
- 235000008599 Poria cocos Nutrition 0.000 claims description 16
- 235000013399 edible fruits Nutrition 0.000 claims description 15
- 229920001542 oligosaccharide Polymers 0.000 claims description 14
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims description 12
- 235000007354 Coix lacryma jobi Nutrition 0.000 claims description 10
- 244000077995 Coix lacryma jobi Species 0.000 claims description 10
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 3
- 241000272814 Anser sp. Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 15
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 14
- 229940116269 uric acid Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 201000005569 Gout Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- -1 amine group oligosaccharide Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开一种含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法,该含鹅肌肽的鱼多肽干粉的制备方法,包括以下步骤:将金枪鱼肉绞碎,漂洗,经漂洗液漂洗,喷雾干燥,得到鱼多肽干粉。上述含鹅肌肽的鱼多肽干粉的制备方法,以金枪鱼为原料制备,工艺简单,成本较低,效果稳定。其制得的降尿酸肽组合物,各组分相互配合、配伍合理,制备得到一种安全、高效、无任何副作用的具有显著降尿酸作用的降尿酸肽组合物料。
Description
技术领域
本发明涉及保健品领域,特别是涉及含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法。
背景技术
目前市面上存在很多降尿酸药物,可以把他们分为以下几类:(1)抑制尿酸 合成药。其代表药是别嘌醇(别嘌呤醇)。别嘌醇及代谢物氧嘌呤醇能抑制黄嘌呤 氧化酶的活性,而使次黄嘌呤转变为尿酸的生化过程受阻而减少尿酸生成。(2) 促进肾脏排泄尿酸药。常用的促肾排尿酸药有苯溴马隆(痛风利仙)、丙磺舒(羧 苯磺胺)等。该类药物主要通过抑制近端肾小管对尿酸的重吸收而促进尿酸的排 泄。主要用于无明显肾功能损害、60岁以下的痛风或高尿酸血症病人,尤适用 于痛风结节较多者。(3)促进肠道排泄尿酸药。代表药为爱西特。它是一种极微 粒化活性炭,口服后在肠道吸附尿酸、肌酐等物质,增加肠道有害物的排出。 (4)消炎、镇痛药物。代表药物秋水仙碱。秋水仙碱通过降低白细胞活动和吞噬 作用,减少乳酸形成而减少尿酸盐的沉积,从而起到减轻炎症和止痛的作用。 总的来说,以上针对尿酸偏高、痛风患者的药物都存在很大的副作用,并不能 作为解决此问题的最佳方案,长期服用对人体造成极大伤害,治标不治本。另 外,加上用药不当,吃吃停停,容易引发并发症。
最近几年随着对金枪鱼的研究,金枪鱼多肽中鹅肌肽、肌肽的神奇功能的出现让无数高尿酸、痛风患者见到了希望。目前,日本、韩国、中国台湾等都有相关的产品,反响良好。作为纯食品,不仅做到了功效强大,而且还解决了安全、无副作用的问题。市面上也出现主打鹅肌肽功效成分的降酸产品,通过调研分析,鹅肌肽原料均来自于日本烧津水产化学工业株式会社,这一方面说明在行业内大家对鹅肌肽的认可,另一方面可以看出国内同行业对鹅肌肽研究几乎为零,主要通过采购,在技术层面上很大程度受制于人,难以确保产品品质及降酸效果稳定。
发明内容
基于此,有必要针对现有的鹅肌肽依赖进口、产品品质难以保证的问题,提供一种降尿酸肽组合物、饮料及制备方法。
一种含鹅肌肽的鱼多肽干粉的制备方法,包括以下步骤:
将金枪鱼肉绞碎,漂洗,经漂洗液漂洗,喷雾干燥,得到鱼多肽干粉。
进一步地,其特征在于,漂洗液为xx漂洗液。
一种降尿酸肽组合物,包括以下组分:以重量份计,4~6份壳寡糖、5~7份茯苓粉、6~11份薏米粉、25~37份水果粉和42~52份含鹅肌肽的鱼多肽干粉。
进一步地,包括以下组分:4~5份壳寡糖、6~7份茯苓粉、8~9份薏米粉、 31~33份水果粉和45~48份含鹅肌肽的鱼多肽干粉。
进一步地,包括以下组分:以重量份计,4.32份壳寡糖、6.32份茯苓粉、 8.95份薏米粉、32.56份水果粉和47.55份含鹅肌肽的鱼多肽干粉。
一种降尿酸肽饮料,所述降尿酸肽饮料为粉剂。
一种降尿酸肽饮料的制备方法,包括以下步骤:
根据重量比准备壳寡糖、茯苓、薏米、水果粉、含鹅肌肽的鱼多肽干粉;
将上述原料进行超微粉碎,分装。
上述含鹅肌肽的鱼多肽干粉的制备方法,以金枪鱼为原料制备,工艺简单,成本较低,效果稳定。
壳寡糖是自然界中唯一带正电荷阳离子碱性氨基低聚糖,是动物性纤维素。壳寡糖是由来源于虾蟹壳的壳聚糖降解成的带有氨基的小分子寡糖,是聚合度2-20的糖链。对人体的免疫调节、抗肿瘤、降血脂、调节血糖、改善肝脏和心肺功能及其他多种生理功能有着重要作用。还可作为肠道益生菌(如双岐杆菌) 的活化因子,增进钙及矿物质的吸收。并且可作为天然防腐产品替代苯甲酸钠等化学防腐剂。
茯苓,味甘、淡,性平,利水渗湿,健脾,宁心,用于水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。
薏米,甘淡、微寒、无毒。入脾、胃、肺、大肠。清热利湿,除风湿,利小便,益肺排脓,健脾胃,强筋骨。主治风湿身痛,湿热脚气,湿热筋急拘挛,湿痹,水肿,肺萎肺痈,咳吐脓血,喉痹痈肿,肠痈热淋。
含鹅肌肽的鱼多肽干粉,鹅肌肽具有降低尿酸的功能。水果粉可使降尿酸肽组合物口感更为舒适。
上述降尿酸肽组合物,各组分相互配合、配伍合理,制备得到一种安全、高效、无任何副作用的具有显著降尿酸作用的降尿酸肽组合物料。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂,下面对本发明的具体实施方式做详细的说明。在下面的描述中阐述了很多具体细节以便于充分理解本发明。但是本发明能够以很多不同于在此描述的其它方式来实施,本领域技术人员可以在不违背本发明内涵的情况下做类似改进,因此本发明不受下面公开的具体实施的限制。
本发明公开了一种含鹅肌肽的鱼多肽干粉的制备方法,包括以下步骤:
将金枪鱼肉绞碎,漂洗,经漂洗液漂洗,喷雾干燥,得到鱼多肽干粉。
具体的步骤如下,原料(金枪鱼)-去头去内脏-清冼-取肉机取肉-绞肉机绞肉-鱼肉漂洗-漂洗液-喷雾干燥-鱼多肽干粉(富含鹅肌肽)。
进一步地,漂洗液为xx漂洗液。
一种降尿酸肽组合物,包括以下组分:以重量份计,4~6份壳寡糖、5~7份茯苓粉、6~11份薏米粉、25~37份水果粉和42~52份含鹅肌肽的鱼多肽干粉。
进一步地,包括以下组分:4~5份壳寡糖、6~7份茯苓粉、8~9份薏米粉、31~33份水果粉和45~48份含鹅肌肽的鱼多肽干粉。
进一步地,包括以下组分:以重量份计,4.32份壳寡糖、6.32份茯苓粉、 8.95份薏米粉、32.56份水果粉和47.55份含鹅肌肽的鱼多肽干粉。
一种降尿酸肽饮料,所述降尿酸肽饮料为粉剂。粉剂保质期长,每袋取适量水溶解,制成饮料,服用方便。
一种降尿酸肽饮料的制备方法,包括以下步骤:
根据重量比准备壳寡糖、茯苓、薏米、水果粉、含鹅肌肽的鱼多肽干粉;
将上述原料进行超微粉碎,分装。
实施例1
一种降尿酸肽组合物包括:4克壳寡糖、7克茯苓粉、6克薏米粉、37克水果粉和42克含鹅肌肽的鱼多肽干粉。
含鹅肌肽的鱼多肽干粉可用市售的含鹅肌肽的鱼多肽干粉,如肇庆兴亿海洋生物工程有限公司生产的含鹅肌肽的鱼多肽干粉,也可采用如下方法制得:金枪鱼-去头去内脏-清冼-取肉机取肉-绞肉机绞肉-鱼肉漂冼-漂冼液-喷雾干燥-含鹅肌肽的鱼多肽干粉。
实施例2
一种降尿酸肽组合物包括:6克壳寡糖、5克茯苓粉、25克薏米粉、52克水果粉和52克含鹅肌肽的鱼多肽干粉。
含鹅肌肽的鱼多肽干粉可用市售的含鹅肌肽的鱼多肽干粉,如肇庆兴亿海洋生物工程有限公司生产的含鹅肌肽的鱼多肽干粉,也可采用如下方法制得:金枪鱼-去头去内脏-清冼-取肉机取肉-绞肉机绞肉-鱼肉漂冼-漂冼液-喷雾干燥-含鹅肌肽的鱼多肽干粉。
实施例3
一种降尿酸肽组合物包括:4.32克壳寡糖、6.32克茯苓粉、8.95克薏米粉、 32.56克水果粉和47.55克含鹅肌肽的鱼多肽干粉。
含鹅肌肽的鱼多肽干粉可用市售的含鹅肌肽的鱼多肽干粉,如肇庆兴亿海洋生物工程有限公司生产的含鹅肌肽的鱼多肽干粉,也可采用如下方法制得:金枪鱼-去头去内脏-清冼-取肉机取肉-绞肉机绞肉-鱼肉漂冼-漂冼液-喷雾干燥-含鹅肌肽的鱼多肽干粉。
临床试验
选择40~70岁年纪阶段出现了痛风症状的男性女性各80名,分为4组,各组包括20名男性,20名女性,记录每组成员的尿液中的尿氮素、尿酸含量。分别服用实施例1~3中的降尿酸肽组合物和安慰剂。其中实施例1~3中的降尿酸肽组合物为一袋的用量,将其加入适量水冲服。早晚各服用一次。服用一个月后对服用者的症状及尿液中的尿氮素、尿酸含量进行检测至进行考察,考察数据见表1。
表1、服用者的痛风症状、尿氮素、尿酸考察结果
可见大部分服用者在服用一个月后,痛风症状缓解或部分消失,尿氮素含量和尿酸含量均下降至合格水平。可见,上述的降尿酸肽组合物具有降低尿酸含量,治疗痛风的作用。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (7)
1.一种含鹅肌肽的鱼多肽干粉的制备方法,其特征在于,包括以下步骤:
将金枪鱼肉绞碎,漂洗,经漂洗液漂洗,喷雾干燥,得到鱼多肽干粉。
2.根据权利要求1所述的含鹅肌肽的鱼多肽干粉的制备方法,其特征在于,所述漂洗液为金枪鱼漂洗液。
3.一种降尿酸肽组合物,其特征在于,包括以下组分:以重量份计,4~6份壳寡糖、5~7份茯苓粉、6~11份薏米粉、25~37份水果粉和42~52份含鹅肌肽的鱼多肽干粉。
4.根据权利要求3所述的降尿酸肽组合物,其特征在于,包括以下组分:以重量份计,4~5份壳寡糖、6~7份茯苓粉、8~9份薏米粉、31~33份水果粉和45~48份含鹅肌肽的鱼多肽干粉。
5.根据权利要求4所述的降尿酸肽组合物,其特征在于,包括以下组分:以重量份计,以重量份计,4.32份壳寡糖、6.32份茯苓粉、8.95份薏米粉、32.56份水果粉和47.55份含鹅肌肽的鱼多肽干粉。
6.一种降尿酸肽饮料,其特征在于,所述降尿酸肽饮料为粉剂。
7.一种权利要求6所述的降尿酸肽饮料的制备方法,其特征在于,包括以下步骤:
根据重量比准备壳寡糖、茯苓、薏米、水果粉、含鹅肌肽的鱼多肽干粉;
将上述原料进行超微粉碎,分装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810215529.3A CN108576367A (zh) | 2018-03-15 | 2018-03-15 | 含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810215529.3A CN108576367A (zh) | 2018-03-15 | 2018-03-15 | 含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108576367A true CN108576367A (zh) | 2018-09-28 |
Family
ID=63626434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810215529.3A Pending CN108576367A (zh) | 2018-03-15 | 2018-03-15 | 含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108576367A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109620948A (zh) * | 2019-01-17 | 2019-04-16 | 湖南省能将通风康复有限公司 | 高尿酸/痛风的全自然细胞调理方法 |
CN113424895A (zh) * | 2021-07-16 | 2021-09-24 | 安徽天凯生物科技有限公司 | 一种具有辅助降尿酸功能的压片糖果配方 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103446175A (zh) * | 2013-09-03 | 2013-12-18 | 中国海洋大学 | 水溶性氨基糖在制备治疗高尿酸血症、痛风、肾病的药物和保健品中的应用 |
CN104643068A (zh) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | 一种用于痛风患者食用的含壳寡糖杜仲雄花粉膳食配方 |
CN104789623A (zh) * | 2015-04-30 | 2015-07-22 | 无限极(中国)有限公司 | 一种蛋白肽的制备方法、蛋白肽及其应用 |
CN106805234A (zh) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | 一种降尿酸食品组合物 |
CN107136377A (zh) * | 2017-06-21 | 2017-09-08 | 武汉万松堂健康产业有限公司 | 一种针对痛风及高尿酸人群的复合固体饮料及其制备方法 |
CN107753801A (zh) * | 2017-12-06 | 2018-03-06 | 周勇 | 降尿酸、降嘌呤治疗痛风的药物组合物及其制备方法 |
-
2018
- 2018-03-15 CN CN201810215529.3A patent/CN108576367A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103446175A (zh) * | 2013-09-03 | 2013-12-18 | 中国海洋大学 | 水溶性氨基糖在制备治疗高尿酸血症、痛风、肾病的药物和保健品中的应用 |
CN104643068A (zh) * | 2015-01-31 | 2015-05-27 | 扬州日兴生物科技股份有限公司 | 一种用于痛风患者食用的含壳寡糖杜仲雄花粉膳食配方 |
CN104789623A (zh) * | 2015-04-30 | 2015-07-22 | 无限极(中国)有限公司 | 一种蛋白肽的制备方法、蛋白肽及其应用 |
CN106805234A (zh) * | 2016-12-19 | 2017-06-09 | 江苏红瑞制药有限公司 | 一种降尿酸食品组合物 |
CN107136377A (zh) * | 2017-06-21 | 2017-09-08 | 武汉万松堂健康产业有限公司 | 一种针对痛风及高尿酸人群的复合固体饮料及其制备方法 |
CN107753801A (zh) * | 2017-12-06 | 2018-03-06 | 周勇 | 降尿酸、降嘌呤治疗痛风的药物组合物及其制备方法 |
Non-Patent Citations (3)
Title |
---|
何雄等: "肌肽的提取分离与生物活性的研究进展 ", 《海洋科学》 * |
刘洋等: "壳寡糖对酵母联合腺嘌呤致高尿酸血症小鼠的治疗作用 ", 《中国海洋大学学报(自然科学版)》 * |
章超桦等主编: "《水产风味化学》", 30 September 2012, 中国轻工业出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109620948A (zh) * | 2019-01-17 | 2019-04-16 | 湖南省能将通风康复有限公司 | 高尿酸/痛风的全自然细胞调理方法 |
CN113424895A (zh) * | 2021-07-16 | 2021-09-24 | 安徽天凯生物科技有限公司 | 一种具有辅助降尿酸功能的压片糖果配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102077933B (zh) | 一种高尿酸患者专用的海洋特膳食品 | |
CN101606704B (zh) | 一种具有多种功能作用的膳食纤维食品 | |
TWI235660B (en) | Drugs against articular failure | |
KR101738912B1 (ko) | 비만억제 및 다이어트 조성물 | |
CN105029447A (zh) | 一种含有活性益生菌的海洋鱼低聚肽粉 | |
CN104855967A (zh) | 肥胖、减脂手术非全营养配方食品 | |
CN102077934A (zh) | 一种高血压患者专用的海洋特膳食品 | |
CN102077940A (zh) | 一种冠心病患者专用的海洋特膳食品 | |
CN102077939A (zh) | 一种肥胖人士专用的海洋特膳食品 | |
CN102077945A (zh) | 一种人流、产后专用的海洋特膳食品 | |
CN102423487A (zh) | 一种骨关节保健组合物及其应用 | |
CN102077944B (zh) | 一种前列腺患者专用的海洋特膳食品 | |
CN104856059A (zh) | 一种减肥的保健营养粉 | |
CN106418501A (zh) | 一种具有减肥功能的保健食品 | |
CN106820151A (zh) | 一种双壳复合保健组合物、制备方法及应用 | |
CN108576367A (zh) | 含鹅肌肽的鱼多肽干粉、降尿酸肽组合物、饮料及制备方法 | |
CN111802653A (zh) | 一种金枪鱼低聚肽粉组合物及其制备方法和应用 | |
CN104783168A (zh) | 一种治疗腹泻的复配营养粉 | |
CN115671132B (zh) | 一种益生菌和益生元的组合物及其应用 | |
CN109620948A (zh) | 高尿酸/痛风的全自然细胞调理方法 | |
CN108308610A (zh) | 一种具有减肥养生功能的中药保健制剂 | |
CN110313599A (zh) | 一种降尿酸果冻及其制备方法 | |
CN114191515A (zh) | 一种祛湿健胃、提高免疫能力口服凝胶及其制备方法 | |
US10434066B2 (en) | Solid drink for regulating yang-deficiency constitution and processing method thereof | |
CN116268414A (zh) | 一种改善胃肠道功能、防治便秘的组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |
|
RJ01 | Rejection of invention patent application after publication |